



Conjupri® (levamlodipine) – New drug approval

- On December 20, 2019, [CSPC Pharmaceutical Group announced](#) the FDA approval of [Conjupri \(levamlodipine\)](#), for the treatment of hypertension in adults and pediatric patients 6 years and older, to lower blood pressure.
- Levamlodipine is the pharmacologically active isomer of [amlodipine](#), a long-acting calcium channel blocker.
- Warnings and precautions for Conjupri include hypotension, increased angina or myocardial infarction, and patients with hepatic failure.
- The most common adverse reaction with amlodipine use is edema which occurs in a dose related manner. Other adverse experiences not dose related (> 1.0%) with amlodipine use are fatigue, nausea, abdominal pain, and somnolence.
- The recommended initial antihypertensive dose of Conjupri in adult patients is 2.5 mg orally once daily, and the maximum dose is 5 mg once daily.
 - The effective antihypertensive oral dose in pediatric patients ages 6 to 17 years is 1.25 mg to 2.5 mg once daily. Doses in excess of 2.5 mg daily have not been studied in pediatric patients.
- CSPC Pharmaceutical Group's launch plans for Conjupri are pending. Conjupri will be available as 1.25 mg, 2.5 mg, and 5 mg tablets.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.